Aliskiren and losartan trial in non-diabetic chronic kidney disease
Conclusion:
This study in non-diabetic CKD patients showed that combination therapy with aliskiren and ARB was as efficacious as aliskiren alone and ARB alone. There was one patient who developed a non-fatal stroke in the combined aliskiren and ARB group while the other two groups had none.
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - Category: Biomedical Science Authors: Woo, K.-T., Choong, H.-L., Wong, K.-S., Tan, H.-K., Foo, M., Fook-Chong, S., Lee, E. J., Anantharaman, V., Lee, G. S., Chan, C.-M. Tags: Original Articles Source Type: research
More News: Biomedical Science | Chronic Kidney Disease | Clinical Trials | Cozaar | Diabetes | Endocrinology | Losartan | Proteinuria | Renal Failure | Stroke | Study | Tekturna | Urology & Nephrology